References
- Birkett DJ, Andersson T, Miners JO. (1996). Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. Methods Enzymol 272:132–9
- Emoto C, Yoda N, Uno Y, et al. (2013). Comparison of P450 enzymes between cynomolgus monkeys and humans: P450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles. Curr Drug Metab 14:239–52
- Koyanagi T, Nakanishi Y, Murayama N, et al. (2015). Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole, and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. Xenobiotica 45:312–21
- Lappin G, Kuhnz W, Jochemsen R, et al. (2006). Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 80:203–15
- Mandagere AK, Thompson TN, Hwang KK. (2002). Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304–11
- Mogi M, Toda A, Iwasaki K, et al. (2012). Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. J Toxicol Sci 37:1157–64
- Murayama N, van Beuningen R, Suemizu H, et al. (2014). Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of pregnane X receptor. Chem Res Toxicol 27:304–8
- National Research Council of the National Academies, Committee for the Update of the Guide for the Care and Use of Laboratory Animals. 2011. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press
- Rendic S, Guengerich FP. (2012). Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25:1316–83
- Ryu JY, Song IS, Sunwoo YE, et al. (2007). Development of the “Inje cocktail” for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82:531–40
- Sasaki E. (2015). Prospects for genetically modified non-human primate models, including the common marmoset. Neurosci Res 93:110–15
- Shida S, Utoh M, Murayama N, et al. (2015). Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica, in press
- Shimizu M, Iwano S, Uno Y, et al. (2014). Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. PLoS One 9:e100936
- Turpault S, Brian W, Van HR, et al. (2009). Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68:928–35
- Uehara S, Uno Y, Hagihira Y, et al. (2015a). Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol, and dextromethorphan. Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2015.1019595
- Uehara S, Uno Y, Inoue T, et al. (2015b). Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). Drug Metab Dispos 43:735–42
- Uehara S, Uno Y, Inoue T, et al. (2015c) Substrate selectivities and catalytic activities of marmoset liver cytochrome P450 2A6 differed from those of human P450 2A6. Drug Metab Dispos, 43:969–76
- Uno Y, Iwasaki K, Yamazaki H, Nelson DR. (2011). Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 43:346–61
- Uno Y, Matsushita A, Osada N, et al. (2010). Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos 38:209–14
- Yamazaki H, Inoue K, Shaw PM, et al. (1997). Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434–42
- Yamazaki H, Nakamura M, Komatsu T, et al. (2002). Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Express Purif 24:329–37